Supercharge

Paris – September 19, 2026 -- Virbac posted first-half 2026 revenue growth of 7.4% at constant exchange rates and currencies (CERS), lifting its adjusted EBIT margin to 18.8%, up 0.5 percentage points from H1 2025.

Companion animal segment leads growth at 10.0%, farm animal follows at 6.7%

The animal health group's Supercharge platforms, excluding Thyronorm, expanded around 12% at CERS, becoming a key driver of top-line performance. Growth split into a volume/mix effect of approximately 5.4% and a price increase of roughly 2%.

Net income climbs 5.9% to €87.1 million

The margin gain stemmed from a favorable gross margin mix, partially offset by higher operating expenses tied to H1/H2 phasing effects.